Prevention of Jellyfish Stings

StatusCompleted
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv7
  2. Lead sponsor: Boulware, David R, MD to University of Minnesotav6
  3. 2 versions Re-verified since Jun 2, 2020, no change to tracked fieldsv4-v5
  4. Primary completion date: Jan 2006
    • Study completion date: Feb 2005 to Feb 2006
    • Interventions: Safe Sea ™ (Drug) to Placebo (Other), Safe Sea ™ (Other)
    • Study arms: 0 to 2
    v3
  5. Interventions: Safe Sea (TM) (Drug) to Safe Sea ™ (Drug)
    • Secondary endpoints: details revised at 2 of 2 entries
    v2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Jellyfish stings are a common occurrence among ocean-goers worldwide with an estimated 150 million envenomations annually. Fatalities and hospitalizations occur annually, particularly in the Indo-Pacific regions. A new topical jellyfish sting inhibitor based on the mucous coating of the clown fish prevents 85% of jellyfish stings in laboratory settings. The field effectiveness is unknown. This is a field test to determine the real world effectiveness.
Trial Details
NCT Number NCT00114894
Lead Sponsor University of Minnesota
Conditions
(from sponsor)		 Bites and Stings
Related terms Bites and Stings
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov